Limits...
Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction.

Martinelli D, Fortunato F, Cappelli MG, Cozza V, Chironna M, Prato R - J Immunol Res (2015)

Bottom Line: The impact of URV among ≤ 18-year-olds was assessed by attributable benefit, preventable fraction, and prevented fraction.Attributable benefit of URV was -0.5 cases per 100,000, preventable fraction 19.6%, and prevented fraction 31.3%.The multicomponent serogroup B meningococcal vaccine has the potential to further prevent at least three other cases/year.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical and Surgical Sciences, University of Foggia, Via Napoli 20, 71122 Foggia, Italy.

ABSTRACT
In Italy, the meningococcal C conjugate vaccine (MenC) has been offered in most regions since 2009-2010. The incidence of Invasive Meningococcal Disease (IMD) was 0.25 confirmed cases per 100,000 in 2011, but this may be considerably underestimated due to underdetection and underreporting. This study estimates the impact of the MenC universal vaccination (URV) in the Puglia region by assessing the completeness of three registration sources (notifications, hospitalizations, and laboratory surveillance). Capture-recapture analysis was performed on meningococcal meningitis collected within 2001-2013. The impact of URV among ≤ 18-year-olds was assessed by attributable benefit, preventable fraction, and prevented fraction. Missed opportunities for vaccination were evaluated from surveillance of IMD. The proportion of detected serogroups was applied to the number of IMD in the postvaccination period to compute the cases still preventable. The sensitivity of the three sources was 36.7% (95% CI: 17.5%-57.9%) and registrations lost nearly 28 cases/year in the period. Attributable benefit of URV was -0.5 cases per 100,000, preventable fraction 19.6%, and prevented fraction 31.3%. Three adolescent cases missed the opportunity to be vaccinated. The multicomponent serogroup B meningococcal vaccine has the potential to further prevent at least three other cases/year. Vaccination strategy against serogroup B together with existing programmes makes IMD a 100% vaccine-preventable disease.

No MeSH data available.


Related in: MedlinePlus

Prevented fraction of IMD cases ≤18 years of age and vaccination coverage against meningococcus C in the Puglia region, within 2001–2013, by vaccine efficacy (VE [27]). (a) Estimated PedF for VC of 57.3% among subjects ≤18 years of age, assuming VE of 83–100%. (b) Estimated VC among subjects ≤18 years of age for PedF of 31.3%, assuming VE of 83–100%.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4553333&req=5

fig3: Prevented fraction of IMD cases ≤18 years of age and vaccination coverage against meningococcus C in the Puglia region, within 2001–2013, by vaccine efficacy (VE [27]). (a) Estimated PedF for VC of 57.3% among subjects ≤18 years of age, assuming VE of 83–100%. (b) Estimated VC among subjects ≤18 years of age for PedF of 31.3%, assuming VE of 83–100%.

Mentions: Vaccination coverage against meningococcus C among subjects ≤18 years old was 57.3%. Thus, the prevented fraction could be estimated to vary between 18.4% and 22.2% for a VE of 83–100%. (Figure 3(a)). On the other hand, an observed prevented fraction of 31.3% implied that vaccination coverage could range from 80.8% to 97.4% (Figure 3(b)).


Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction.

Martinelli D, Fortunato F, Cappelli MG, Cozza V, Chironna M, Prato R - J Immunol Res (2015)

Prevented fraction of IMD cases ≤18 years of age and vaccination coverage against meningococcus C in the Puglia region, within 2001–2013, by vaccine efficacy (VE [27]). (a) Estimated PedF for VC of 57.3% among subjects ≤18 years of age, assuming VE of 83–100%. (b) Estimated VC among subjects ≤18 years of age for PedF of 31.3%, assuming VE of 83–100%.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4553333&req=5

fig3: Prevented fraction of IMD cases ≤18 years of age and vaccination coverage against meningococcus C in the Puglia region, within 2001–2013, by vaccine efficacy (VE [27]). (a) Estimated PedF for VC of 57.3% among subjects ≤18 years of age, assuming VE of 83–100%. (b) Estimated VC among subjects ≤18 years of age for PedF of 31.3%, assuming VE of 83–100%.
Mentions: Vaccination coverage against meningococcus C among subjects ≤18 years old was 57.3%. Thus, the prevented fraction could be estimated to vary between 18.4% and 22.2% for a VE of 83–100%. (Figure 3(a)). On the other hand, an observed prevented fraction of 31.3% implied that vaccination coverage could range from 80.8% to 97.4% (Figure 3(b)).

Bottom Line: The impact of URV among ≤ 18-year-olds was assessed by attributable benefit, preventable fraction, and prevented fraction.Attributable benefit of URV was -0.5 cases per 100,000, preventable fraction 19.6%, and prevented fraction 31.3%.The multicomponent serogroup B meningococcal vaccine has the potential to further prevent at least three other cases/year.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical and Surgical Sciences, University of Foggia, Via Napoli 20, 71122 Foggia, Italy.

ABSTRACT
In Italy, the meningococcal C conjugate vaccine (MenC) has been offered in most regions since 2009-2010. The incidence of Invasive Meningococcal Disease (IMD) was 0.25 confirmed cases per 100,000 in 2011, but this may be considerably underestimated due to underdetection and underreporting. This study estimates the impact of the MenC universal vaccination (URV) in the Puglia region by assessing the completeness of three registration sources (notifications, hospitalizations, and laboratory surveillance). Capture-recapture analysis was performed on meningococcal meningitis collected within 2001-2013. The impact of URV among ≤ 18-year-olds was assessed by attributable benefit, preventable fraction, and prevented fraction. Missed opportunities for vaccination were evaluated from surveillance of IMD. The proportion of detected serogroups was applied to the number of IMD in the postvaccination period to compute the cases still preventable. The sensitivity of the three sources was 36.7% (95% CI: 17.5%-57.9%) and registrations lost nearly 28 cases/year in the period. Attributable benefit of URV was -0.5 cases per 100,000, preventable fraction 19.6%, and prevented fraction 31.3%. Three adolescent cases missed the opportunity to be vaccinated. The multicomponent serogroup B meningococcal vaccine has the potential to further prevent at least three other cases/year. Vaccination strategy against serogroup B together with existing programmes makes IMD a 100% vaccine-preventable disease.

No MeSH data available.


Related in: MedlinePlus